Asset Details
Do you wish to reserve the book?
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease
Do you wish to request the book?
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease
2025
Overview
Lay Summary Patients with IBD are at an increased risk of major adverse cardiovascular events (MACE), potentially due to both atherosclerotic and non-atherosclerotic, inflammation-mediated pathways. In this retrospective cohort study, IBD patients with GLP-1RA use were less likely to have MACE.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.